A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups

References

• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051–62.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013;381:484–95.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. (official journal of the American Society of Clinical Oncology) 2011;29:475–86.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013;121:3563–72.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–5.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–65.
   PubMed Web of Science ®Google Scholar
• Hajkova H, Markova J, Haskovec C, Sarova I, Fuchs O, Kostecka A, et al. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leuk Res. 2012;36:1128–33.
   PubMed Web of Science ®Google Scholar
• Zare-Abdollahi D, Safari S, Movafagh A, Ghadiani M, Riazi-Isfahani S, Omrani MD. Intact expression status of RASSF1A in acute myeloid leukemia. Med Oncol. (Northwood, London, England) 2014;31:770.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, et al. Array-based genomic resequencing of human leukemia. Oncogene 2010;29:3723–3731.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424–33.
   PubMed Web of Science ®Google Scholar
• Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia 2013;27:238–41.
   PubMed Web of Science ®Google Scholar
• Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. (official journal of the American Society of Clinical Oncology) 2011;29:2889–96.
   PubMed Web of Science ®Google Scholar
• Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012;119:5824–31.
   PubMed Web of Science ®Google Scholar
• Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res. 2013;37:1445–50.
   PubMed Web of Science ®Google Scholar
• Pezzi A, Moraes L, Valim V, Amorin B, Melchiades G, Oliveira F, et al. DNMT3A mutations in patients with acute myeloid leukemia in South Brazil. Adv Hematol. 2012;2012:697691.
   PubMedGoogle Scholar
• Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43:309–15.
   PubMed Web of Science ®Google Scholar
• Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis. 2015;54:84–9.
   PubMed Web of Science ®Google Scholar
• Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, et al. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia. Leukemia 2014;28:1227–34.
   PubMed Web of Science ®Google Scholar
• Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491–8.
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 2003;17:2474–86.
   PubMed Web of Science ®Google Scholar
• Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012;12:599–612.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153–8.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001;97:1172–9.
   PubMed Web of Science ®Google Scholar
• Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 2013;27:1891–901.
   PubMed Web of Science ®Google Scholar
• Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci. 2005;96:206–11.
   PubMed Web of Science ®Google Scholar